THOUSAND OAKS, Calif., Jan. 6, 2026 — Amgen announced it will acquire Dark Blue Therapeutics Ltd., a privately held U.K. biotechnology company, in a deal valued at up to $840 million.
The acquisition brings to Amgen an investigational small molecule designed to target and degrade MLLT1 and MLLT3, two proteins implicated in specific forms of acute myeloid leukemia (AML). Preclinical studies in leukemia models showed promising anti-cancer activity and mechanistic differentiation from existing therapies, supporting development as a single agent and in combination to address treatment resistance and improve remission durability.
Jay Bradner, M.D., executive vice president of Research and Development at Amgen, said the company sees an urgent need for new mechanisms to treat AML and that the acquisition complements Amgen’s targeted protein degradation and leukemia research efforts.
Amgen plans to integrate Dark Blue Therapeutics into its existing research organization to strengthen its early oncology discovery capabilities.
Amgen discovers, develops, manufactures and delivers medicines for serious illnesses and maintains a broad pipeline across oncology, cardiovascular disease, bone health, inflammatory and rare diseases. The company is listed on major U.S. indices and reported external recognitions in 2024 for innovation and employment.
Leave a Reply